Merck's Nine valent HPV Vaccine Added Second Dose Vaccination Program Approved for Women Aged 9-14
宋哥TY
发表于 2024-1-9 17:12:34
1311
0
0
Red Star Capital Bureau reported on January 9 that today, the official WeChat official account of "MSD China" announced that the two dose vaccination procedure (June December) for women aged 9-14 years old with the ninvalent human papillomavirus vaccine (Saccharomyces cerevisiae) (trade name: Jiadaxiu 9, namely, the ninvalent HPV vaccine) had been approved by the State Food and Drug Administration.
This approval means that Jiada Xiu 9 will add a second dose vaccination program for 9-14 years old. Prior to this, the Merck Tohmatsu nine valent HPV vaccine used a three dose immunization program, priced at 1318 yuan per dose in public medical institutions, with a total cost of 3954 yuan per dose.
In August 2023, MSD China announced the age expansion of its nine valent HPV vaccine. The target audience has expanded from 16-26 years old to women of appropriate age between 9-45 years old.
In addition, the Merck East Nine valent HPV vaccine remains the only approved and marketed nine valent HPV vaccine in China. Zhifei Biotechnology (300122. SZ) is the exclusive agent and announced at the end of January 2023 that the renewal of the exclusive agency for Merck East HPV vaccine has been successful. The procurement amount has significantly increased from 28.106 billion yuan in the previous agreement period to 97.957 billion yuan.
In terms of domestic manufacturers, Wantai Biotechnology (603392. SH) launched its bivalent HPV vaccine (trade name: Xinkening Cecolin) in May 2020, which was the first domestically produced cervical cancer vaccine to be approved for sale; In May of this year, the first batch of bivalent HPV vaccines produced by Yuxi Zerun, a subsidiary of Watson Biotech (300142. SZ), obtained the "Biological Product Batch Issuance Certificate", marking the arrival of the second bivalent HPV vaccine in China.
According to the official website of the Shanghai Stock Exchange e-interactive platform, on December 14, 2023, Wantai Biotechnology responded to investor inquiries by stating that the on-site work for the V8 phase visit of the company's nine-valent HPV vaccine phase III main clinical trial has been completed and specimen testing is currently underway. Meanwhile, this vaccine can be used as an iterative vaccine for market application.
However, regarding the launch time of its nine valent HPV vaccine, Wantai Biotechnology stated that there are many types of specimen testing and the testing process is complex. After the testing is completed, quality control of the data is also required. The specific time will depend on the progress of each link, and it has developed corresponding promotion plans, which are currently being executed according to the plan.
Red Star News reporter Deng Lingyao
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Eli Lilly and Predator Peptide Approved for Long term Weight Management Indications in China
- Tesla Musk: Expected FSD to be approved and implemented in China before the end of the year
- The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
- JD Allianz Equity Transfer Approved: Allianz Insurance Group to Transfer 53.33% Equity of the Company to Allianz China Holdings
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Intel Technology is expected to complete $8.5 billion in financing by the end of the year; A total of 109 domestic online games were approved in September
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Multiple new indications for Merck drugs approved for market in China
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏